国内自主研发降糖药获批上市！可T+0交易的港股创新药ETF（159567）本周涨6.17%，过去5个交易日获得1.52亿元资金净流入

Core Viewpoint - The approval of Heng Rui Medicine's innovative drug, Regaglitin Metformin, marks a significant advancement in the domestic innovative drug sector, filling a gap in the market for Type 2 diabetes treatment [1] Group 1: Market Performance - Heng Rui Medicine's stock surged over 25% following the drug approval, reflecting strong market enthusiasm for the Hong Kong innovative drug sector [1] - The Hong Kong innovative drug index's price-to-earnings ratio dropped from 64 times on February 21 to 27 times on May 23, indicating a significant reduction in valuation and highlighting attractive investment opportunities [1] Group 2: Industry Trends - The innovative drug sector is experiencing a positive trend, with notable collaborations such as the record-setting upfront payment from 3SBio to Pfizer, showcasing the growing potential of domestic innovative drugs in international markets [1] - The innovative drug ETF (159567) tracks the National Index and has a 90% weight in innovative drug companies, positioning it to benefit from trends like AI-driven drug development and the expansion of domestic innovative drugs [2] Group 3: Clinical Research Advancements - The innovative drug sector has shown significant investment value due to breakthroughs in clinical research and drug development, with promising results expected from multiple domestic innovative drug studies at the upcoming 2025 ASCO conference [3] - New treatment options for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) have demonstrated high objective response rates (ORR) and progression-free survival (PFS), indicating strong potential for commercialization [3]